Recent advances in medical imaging have resulted in improved and earlier detection of tumoral lesions and lymphadenopathy. This development has been accompanied by advances in interventional radiology and endoscopic techniques that allow obtaining tissue samples from virtually any body site through minimally invasive procedures with very low rates of complications. For morphologists, this trend has resulted in progressively smaller tissue samples in which tissue architecture, an important parameter for establishing a histologic diagnosis, is difficult to assess or no longer evaluable. While excisional/large incisional biopsies are ideal for diagnosis and ancillary testing, nowadays in many centers, including ours, the initial diagnostic approach for suspected lymphomas includes fine-needle aspirates (FNAs), FNAs with cell block, and core needle biopsies (CNBs).
1,2 A search of the electronic pathology database at the Minneapolis Veterans Administration (VA) Medical Center showed that the diagnosis of lymphoma in limited samples of lymph nodes (FNAs or CNBs) was 15% in 1991 (n = 26), 20% in 2004 (n = 25), and 70% in 2016 (n = 59). Similarly, AmadorOrtiz et al 1 reported an increase from 28% in 2003 to 70% in 2007 at a tertiary center, reflecting a trend that is occurring in many centers around the world. Difficulties in establishing a reliable diagnosis in these samples have been at least partially offset by continuous advances in ancillary techniques. These techniques provide objective supporting evidence for establishing clonality, assessing cell lineage/aberrant antigenic expression, and evaluating for tumor-specific translocations or mutations. Recent studies on the use of FNAs and CNBs for establishing and subclassifying lymphomas report diagnostic success rates ranging from 75% to 98%. 1, 2 Some of the studies used for pathologic diagnosis have now become targeted therapy-specific ancillary tests (eg, CD20, CD30, CD52, ALK, BCL2). Equally important, the adoption of electronic medical records by most medical centers gives pathologists access to clinical and radiologic information for optimal clinicopathologic correlation.
To guide clinical decision making, the oncologist looks for the following information from the pathologist: Is the lesion benign or malignant? If malignant, is it a lymphoma, and if so, is a definitive subclassification possible? Since each diagnostic category of lymphoma is a unique disease entity with characteristic morphology, immunophenotype, molecular genetics, and gene expression profile, precise identification is of utmost importance for prognostication and therapy. Further evaluation, and the urgency with which it needs to be undertaken, depends on the type and grade of lymphoma: for low-grade lymphoid neoplasms (eg, low-grade follicular lymphoma [FL] , marginal zone lymphoma [MZL] , or small lymphocytic lymphoma [SLL]), workup for staging and determining the need for treatment vs observation can be arranged electively on an outpatient basis. For intermediate-grade lymphomas, such as diffuse large B-cell lymphoma (DLBCL) or grade 3 FL, expedited staging workup, assessment of cardiac function, and initiation of combination chemoimmunotherapy (eg, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] regimen) are indicated. If a high-grade lymphoma is present (eg, Burkitt lymphoma [BL] , acute lymphoblastic leukemia/ lymphoblastic lymphoma [ALL/LBL]), then urgent workup, including assessment of cardiac function and sampling of the cerebrospinal fluid, aggressive hydration, and prophylaxis against tumor lysis followed by initiation of intensive multiagent chemoimmunotherapy and central nervous system (CNS) prophylaxis, usually in the inpatient setting, is required. In addition, identification of specific lymphoma subtypes such as mantle cell lymphoma (MCL), anaplastic large cell lymphoma (ALCL), classical Hodgkin lymphoma (CHL) vs nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), or the presence of molecular therapeutic targets, such as the BCR/ABL translocation, is critical to determination of prognosis and treatment. In addition to a specific diagnosis, the clinician may seek additional information from the pathologist for selection of therapy. For some of the most common lymphoid disorders, these are as follows:
• Chronic lymphocytic leukemia (CLL): Interphase fluorescent in situ hybridization (FISH) for detection of prognostically relevant chromosomal abnormalities, sequencing for TP53 mutations, karyotype for detection of complex cytogenetic abnormalities, and molecular analysis for detection of immunoglobulin heavy chain variable region mutation status. Whether del(17p)/TP53 mutations are present or absent is of particular relevance for prognosis and treatment. 3 • FL: FISH detection of t(14;18), BCL6, 1p36, and IRF4/MUM1 rearrangements to determine whether the lymphoma represents typical FL, FL with 1p36 deletion, or cutaneous or pediatric-type FL (in adults) for planning optimal treatment and prognosis. 4 • DLBCL: Distinguish germinal center B-cell (GCB) vs non-GCB (activated B-cell) cell of origin by ancillary tests. Karyotype or FISH for detection of MYC, BCL2, and BCL6 rearrangements, to identify double-and triple-hit DLBCL. These two aspects (cell of origin and double/triple hit) are of particular relevance for prognosis, optimal treatment, and referral for clinical trials. [4] [5] [6] The interested reader is advised to consult the most current version of standard sources such as the National Comprehensive Cancer Network guidelines for up-todate and detailed information about the specific test results the clinician looks for to determine prognosis and guide treatment for the wide variety of lymphoid malignancies at https://www.nccn.org. The authors describe here their approach to the evaluation of lymphoid lesions, aimed at serving as a guide for the general pathologist.
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Selecting the Optimal Site for Sampling
This important decision is driven by three criteria: 7, 8 In a recent large multicenter study with the SharkCore needle involving 18 large medical centers, the diagnostic yield was 93% for nodal lesions, 7 a result comparable to the 85% to 87% diagnostic yield of CNB specimens in recent studies. 2 The superior diagnostic yield of the EZ Shot 3 Plus needle has been shown for pancreatic tumors, 8 but studies on lymphomas are not available at this time.
• Size and metabolic activity: A legitimate concern about definitively diagnosing low-grade lymphoid lesions in FNA and CNB specimens is the uncertainty that lowgrade lesions may have transformed to intermediate-or high-grade lymphomas in the unsampled portion of the biopsied node or extranodal site. Many pathologists, therefore, feel the need to request excisional biopsies for definitive evaluation. In a recent European study comparing excisional vs CNB biopsies (n = 1,510), excisional biopsies detected transformation in a higher percentage of cases (7.6% vs 3.3%), but the difference was not statistically significant (P = .23). 9 Depending on the tumor stage, lymphomas may affect many nodes and extranodal sites at the time of diagnosis. Sampling the largest or most rapidly enlarging or disproportionately hyperactive lesions on metabolic imaging studies such as positron emission tomography (PET)/CT scans is likely to evaluate the lesions with the highest proliferative activity and grade. However, no method is infallible, as increased uptake may be secondary to inflammation, infection, and/or necrosis. 10 Correlation with laboratory tests (serum lactate dehydrogenase [LDH] , serum β2-microglobulin) and feedback from the oncologist are helpful to determine if the histologic findings are congruent with the clinical scenario.
• Safety: If several nodes appear amenable to sampling, it is prudent to choose the one with the lowest risk of procedure-related injury.
How to Triage the Specimen
ROSE is critical to enhance diagnostic yield of the limited tissue sample and to ensure appropriate collection for required ancillary studies. Diff-Quik stains of FNA or touch imprint smears of CNB specimens are the essential first step in ROSE. Preparation of at least two to four stained or unstained smears for potential use for FISH is possible in most cases. While preparing smears, performing flow cytometry (FCM), and obtaining a tissue sample are ideal, in difficult-to-obtain samples, some studies need to be prioritized, as discussed below. In our hospital, we place needle cores or tissue fragments of samples with a preponderance of lymphoid cells in touch imprints in Roswell Park Memorial Institute medium or saline solution, shake the specimen briefly but thoroughly, retrieve the cores/fragments and place them in formalin for histologic processing, and use the fluid for FCM analysis. This approach prevents the aggregation and nonspecific staining artifacts created by the mechanical or enzymatic dissociation of tissue samples and secures or increases the amount of tissue available for morphologic examination, immunostains, and molecular cytogenetic studies but has a low diagnostic yield in lymphomas associated with sclerosis, a known cause of false-negative flow cytometric results. 11 Reactive lymphoid proliferations frequently demonstrate heterogeneity, with a mix of small mature lymphocytes, centrocytes, centroblasts, immunoblasts, plasma cells, and histiocytes, reflective of the physiologic immune response to antigenic stimuli, while many neoplastic lymphoid processes demonstrate relative monotypic features, indicative of clonal proliferation.
However, there are monotonous-appearing benign lymphoid aspirates (eg, dermatopathic lymphadenopathy) and heterogeneous-appearing lymphomas (eg, FL, MZL, CHL, SLL with increased proliferation centers), and thus, FCM should be performed whenever feasible to assess for clonality. Cellular cohesion is deemed helpful to separate lymphoid from epithelial lesions, yet clustering of lymphocytes can be seen in normal and neoplastic follicles due to the presence of follicular dendritic cells or in samples with increased histiocytes or sclerosis. On the other hand, melanomas and some epithelial tumors (eg, neuroendocrine, lobular carcinoma) show poor cohesion.
In our experience, a more useful approach while evaluating smears is to try to divide the findings into five morphologic categories: (1) marked preponderance of small lymphoid/lymphoid-like cells, (2) preponderance of large cells, (3) similar proportions of small and large cells, (4) preponderance of blast-like cells, and (5) presence of rare large pleomorphic cells. Using reference cells, such as the smallest or largest lymphocyte in the sample depending on which population predominates, or other blood elements (RBCs, neutrophils, macrophages) present in most samples is necessary for this assessment. After this preliminary triage, a panel of studies will assist in reaching a specific diagnosis ❚Table 1❚.
Interpretation

Preponderance of Small Lymphocytes/Lymphoid-Like Cells
These cases show an overwhelming preponderance of small cells ❚Image 1A❚. A cutoff of more than 80% small cells has been recommended in some studies. 12, 13 In these samples, FCM is the most important ancillary test, followed by cell block.
• Since the main differential diagnosis for this type of sample is benign vs low-grade malignancy, detection of low-grade clonal B-lymphocytic populations is best achieved through FCM.
• Standard FCM analysis includes a comprehensive panel of markers for subclassification of low-grade B-cell lymphomas and includes several pan-T-cell markers to analyze T-cell subpopulations.
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• The cell block is important to perform cyclin D1 (CyD1) and SOX11 to recognize MCL in CD5-positive B-cell neoplasms since this has important therapeutic ramifications ❚Table 2❚.
• FCM evidence of a CD10-positive neoplasm in this group is diagnostic of low-grade FL. In cases negative or equivocal for CD10, or in cases without available FCM, the cell block is important to identify coexpression of BCL2 in cells expressing germinal center markers: CD10, BCL6, and/or GC1 for the diagnosis of FL. Expression of BCL2 is normal in T cells and frequent in benign reactive marginal zone cells, many lymphomas, and many benign and malignant epithelial and stromal cells. Thus, interpretation of this stain is only indicative of FL in germinal center B cells.
• A subset of SLL/CLL may lack CD5 expression. 15 Similarly, approximately 10% of MCLs have been shown to be CD5 negative, a feature reported to be associated with a less aggressive outcome. 16, 17 The diagnosis in these atypical cases would be dependent on other immuno-morphologic features (SLL/CLL with dim expression of both CD20 and surface immunoglobulin [sIg] light chains on FCM and the presence of proliferation centers; CyD1/ SOX11 expression in MCL).
• FISH studies for CyD1 (CCND1), BCL2, or BCL6 rearrangements (REA) to confirm the diagnosis of MCL or FL, respectively, can also be done in cytologic smears if a cell block is not available or if other ancillary studies are inconclusive.
• A diagnosis of reactive hyperplasia or a specific subtype of low-grade lymphoma (SLL, MCL, low-grade FL) can be established in limited samples in most cases through correlation with the abovementioned ancillary studies.
• The differential diagnosis for neoplastic cases in this category with an increased percentage of clonally related plasma cells includes MZL and lymphoplasmacytic lymphoma (LPL). These lymphomas overlap in their morphology and immunophenotype (CD5-/ CD10-/CD20+/FCM+), and their subclassification requires correlation with clinical parameters: location and presence or absence and type of associated paraproteinemia. Atypical immunophenotypic features in a subset of all forms of MZL (splenic, extranodal, and nodal) may include aberrant expression of CD5.
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The diagnosis of MZL in these settings would be dependent on demonstration of one or more features such as monocytoid B-cell morphology, follicular colonization with persistence of atrophic germinal centers apparent on CD21 or CD23 immunostains, and a frequent plasmacytic component. Furthermore, bright CD20 and sIg light chain expression and lack of proliferation centers would argue against SLL/CLL, and lack of CyD1 and SOX11 expression should exclude most MCLs. In contrast to pure plasma cell neoplasms, the plasma cells in these cases usually retain expression of CD19 and CD45(dim) and are negative for CD56. For MZL, skin and mucosal sites are the commonest location, with spleen and lymph nodes representing distant second and third sites of affectation. By contrast, LPL is primarily a neoplasm of the bone marrow. 14 MZL is usually associated with a small non-immunoglobulin M (IgM) or occasionally IgM paraproteinemia, while LPL is usually associated with an IgM paraproteinemia proportional to the disease burden but usually large. A recurring mutation in MYD88 L265P can be demonstrated by next-generation sequencing in most (~97%) cases of LPL. 21 Subclassification may not be possible in advanced stages of these lymphomas because a specific primary location can no longer be determined and because bona fide cases of MZL have been shown to harbor the MYD88 L265P mutation, and cases of LPL may be associated with a non-IgM paraproteinemia or be negative for MYD88
L265P
. 22 In those cases, establishing extent of disease burden, immunoglobulin-associated diseases/complications (eg, amyloidosis, cast nephropathy, cryoglobulinemia, hyperviscosity), and presence or absence of high-grade transformation becomes more relevant. A positive MYD88 L265P mutation has been reported to be associated with better response to Bruton's tyrosine kinase inhibitors. 23 • The cell block is also fundamental for excluding lowgrade lymphoma mimics, especially when the clinical scenario is highly suggestive of a malignancy but without the typical clinical features of a lymphoma. Typical morphologic mimics of low-grade lymphomas include well-differentiated neuroendocrine neoplasms, lowgrade basaloid carcinomas, and small cell melanoma; pertinent immunohistochemistry can be performed in the CNB specimen or cell block to resolve this differential diagnosis. 
Preponderance of Large Cells
A cutoff of more than 40% large cells has been recommended to include cases in this category ❚Image 1B❚. 12, 13 In these samples, cell block and smears/imprints for possible FISH studies should be prioritized. A diagnosis of malignancy is evident; however, the lineage of the neoplastic cells is not always obvious. The presence of abundant cytoplasmic fragments (lymphoglandular bodies) is more common in lymphomas but may also be present in other tumors, especially high-grade malignancies. FCM analysis of DLBCL or high-grade lymphomas can expedite the diagnosis of lymphoma, but it can be misleading/equivocal since these lesions are frequently associated with increased apoptotic/necrotic debris that causes nonspecific staining, may not express or underexpress hematopoietic markers and immunoglobulin light chains, and may show lineage infidelity or aberrant phenotypes. A negative flow study does not exclude a high-grade lymphoma. The main goal in this type of sample is to establish lineage through immunostains in the cell block; a panel of pankeratin cocktail (epithelial), CD43/CD45 cocktail (hematopoietic), and SOX10 (melanocytic) is adequate in most cases. 24 Adding CD43 to CD45 allows the detection of those hematolymphoid neoplasms that show weak expression or are negative for CD45-like blastic neoplasms, anaplastic lymphomas, and plasma cell/plasmacytic neoplasms. Most lymphoid neoplasms are of the B-cell lineage, and a useful initial panel for this group includes CD3, CD5, CD10, CD20, CD30, CyD1, BCL2, BCL6, MUM1, Ki-67, and chromogenic or conventional in situ hybridization for Epstein-Barr virus (EBV-ISH/CISH). This panel allows immunohistochemical classification of DLBCL into GCB and non-GCB types (Table 1) , recognition of the pleomorphic variant of mantle cell lymphoma (CD5+/ CyD1+), Richter transformation in patients with a history of CLL/SLL and de novo CD5+ DLBCL (CD5+/ CyD1-) in those without, and EBV-related lymphomas. Most oncologists expect, and many clinical trials require, subclassification of DLBCL into GCB and non-GCB types since GCB type has an overall better prognosis and response to R-CHOP therapy. 4, 14 Although the gold standard for making this distinction is gene expression profiling (GEP), technical and cost consideration aspects have led to development of surrogate immunohistochemical algorithms for this purpose. The Hans algorithm 25 (Table 1) is the most widely used method, although recent modifications using newer markers like GCET and FOXP1 have shown higher correlation with GEP (93% vs 80%). ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; B-ALL, B-cell acute lymphoblastic leukemia/lymphoma; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; BR, bendamustine and rituximab; CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CNS, central nervous system; CODOX-M IVAC, cyclophosphamide, doxorubicin, and vincristine with intrathecal methotrexate and cytarabine followed by high-dose systemic methotrexate, alternating with IVAC (ifosfamide, cytarabine, etoposide, and intrathecal methotrexate); DLBCL, diffuse large B-cell lymphoma; FCR, fludarabine, cyclophosphamide, and rituximab; hyper-CVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, and cytarabine; NOS, not otherwise specified; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP, rituximab, cyclophosphamide, vincristine, and prednisone; R-EPOCH, rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (infusional regimen); R-hyper-CVAD, rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, and cytarabine; RT, radiation therapy; SLL/CLL, small lymphocytic lymphoma/chronic lymphocytic leukemia; Stanford V, doxorubicin, vinblastine, mechlorethamine, etoposide, vincristine, bleomycin, and prednisone; TKI, tyrosine kinase inhibitor.
When to Test for MYC Rearrangement (MYC REA )?
MYC-rearranged lymphomas are characterized by a high proliferative rate that clinically translates into bulky disease, high LDH and β2-microglobulin levels in serum, rapid clinical progression, advanced stage, increased incidence of CNS involvement, and increased risk of tumor lysis syndrome. 6, 27 Morphologically, these lymphomas can show DLBCL or BL-like morphology. Most cases show a median Ki-67 proliferative rate of 90% or more, but cases with proliferation rates as low as 30% have been reported. 27 Since systematic studies of cases with MYC REA and low proliferative rates are not available, the current World Health Organization (WHO) classification does not endorse any immunohistochemical preselection method for MYC REA testing, essentially implying it should be performed in most if not all cases of large B-cell lymphomas.
14 MYC FISH cannot be replaced by MYC immunohistochemistry (IHC) because most studies have shown inadequate correlation between both methods.
14 Some authors recommend MYC IHC for screening which cases need confirmatory FISH, using cutoff values between 30% and 40% positive nuclei. 28 FISH is preferably done in cytologic preparations because interpretation is easier in whole nuclei and can be done in previously stained or unstained cytologic preparations but can also be performed in paraffin-embedded tissue. If MYC is rearranged, additional testing for BCL2 and BCL6 REA should follow to identify "double-and triple-hit" (MYC ± BCL2 ± BCL6) lymphomas (DHLs/ THLs), which pursue a much more aggressive course than DLBCL, with average survivals of less than 12 months when treated with conventional DLBCL regimens. 6, 14, 27 In the largest multicenter study on therapy for DHL/THL to date, Petrich et al 29 showed improved outcomes with intensive chemotherapy regimens and CNS prophylaxis; the most commonly used regimen was dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, given the possibility of adjusting the dose to the condition of the patient and side effects, but the benefit was limited in patients with advanced stage disease. Amplification without rearrangement of these genes is common but is not currently considered a criterion to include these cases in the DHL/THL category, 14 even when recent studies have reported that this finding usually correlates with a more aggressive disease course than standard DLBCL. 30, 31 Similarly, acquired MYC REA in subclones of preexisting lymphomas (MCL, FL, SLL, ALL, plasmablastic) or plasma cell neoplasms are also not considered DHL/THL but are classified as MYC-rearranged high-grade B-cell lymphoma (HGBCL) evolved from preexisting "specific-type lymphoma" or "MYC-rearranged aggressive plasma cell neoplasm" 14, 32 ; in general, these tumors also behave more like DHL/THL than regular transformation to DLBCL. 32 As more information is gained, it appears likely that the DHL/THL category will be expanded to include cases with MYC and BCL2 and/or BCL6 amplifications and MYC REA superimposed on preexistent IGH-BCL2 or IGH-CCND1 or other translocations. [30] [31] [32] [33] Cases lacking MYC REA but showing immunohistochemical overexpression of MYC and BCL2 are usually referred to as "double expressor or dual protein expressor (DE/DPE) DLBCL" if the cells are large or "DE/DPE-HGBCL" if the cells show BL-like morphology. While these cases are not formally recognized by the WHO as a distinct category, most studies have shown that they pursue a worse clinical course than conventional DLBCL but better than DHL when treated with R-CHOP and have a higher risk of CNS relapse. 34, 35 This is not surprising, since most of these cases are non-GCB DLBCL/HGBCL with high proliferative activity. A precise definition of this category will require standardization of MYC and BCL2 IHC across laboratories given the different existing clones, staining heterogeneity, frequent crush artifact/necrosis, and different cutoff levels for positivity used in different studies. 36 Commonly used cutoffs for MYC and BCL2 overexpression are more than 40% and more than 50% to 70%, respectively. Intensity of staining is not considered for interpretation.
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Similar Proportion of Small and Large Cells
Recommended cutoff for including cases in this category is 20% to 40% large cells ❚Image 1C❚. 12, 13 Both FCM and cell block are necessary; the workup is the same as in samples with a preponderance of large cells (see above). Any significant component of large cells in a lymphoid neoplasm should be regarded as potentially indicative of an intermediate-or high-grade process. The differential diagnosis typically includes reactive follicular hyperplasia (CD10+/BCL2-/BCL6+/FCM-), high-grade or transformed FL (CD10+/BCL2+/BCL6+), partial involvement by DLBCL, pleomorphic MCL (CD5+/CD20+/CyD1+), Richter's transformation of SLL (CD5+/CD20+/CyD1-in small and large cells), and partial involvement by nonhematopoietic neoplasms, especially melanomas and high-grade neuroendocrine tumors. These cases require a careful evaluation of the phenotype of the small and large cell components separately. The small cell component may consist of benign reactive T cells, the low-grade component of a transformed neoplasm (usually characterized by marked preponderance of B over T cells in the background), or an incidental unrelated concurrent low-grade lymphoma, which would show a divergent immunophenotype (composite lymphoma). 14,28 Cases negative for MYC REA are classified as HGBCL not otherwise specified (NOS). It has been recently shown that a subset of classic BL and MYC REA -negative BL-like lymphomas has abnormalities of 11q (duplication, inversion, deletion) that can be detected with the FISH probes used for detecting MLL/11q23/KMT2A rearrangements. Reports on these cases are limited, but they behaved and responded to therapy like classic BL. 38 Nonhematopoietic differential diagnosis for cases with very high mitotic/apoptotic activity typically includes high-grade neuroendocrine carcinomas (small cell, Merkel). Expression of sIg by FCM excludes B-lymphoblastic lymphoma/leukemia because immunoglobulin genes are in the germline configuration in B lymphoblasts. If surface light chains cannot be demonstrated, blast markers should be added to the FCM panel. If flow is not available or is inconclusive, tissue immunohistochemistry should include blast markers: CD34 and TdT. Cases positive for CD20/CD5/ CyD1 should be classified as blastoid MCL, and cases negative for blastic markers and CyD1 are classified as HGBCL NOS. Cases expressing blast markers (CD34, TdT) require subclassification into T-or B-ALL/LBL according to the lineage-specific markers: CD3 = T, CD19 ± CD22 ± PAX5 ± CD79a = B. Conventional cytogenetics is prognostically relevant in ALL/LBL in general and may require obtaining additional samples if the staging bone marrow biopsy specimen is negative. The BCR-ABL status is particularly relevant for therapy in B-ALL/ LBL (Table 2 ). This test can be performed in smears and tissue blocks by FISH. In cases where a T-or B-cell lineage cannot be demonstrated, myeloid (myeloperoxidase, lysozyme) and blastic plasmacytoid dendritic cell markers (CD4, CD56, CD123, TCL1) should be added, especially in mucocutaneous lesions. Nonhematopoietic differential diagnosis for cases with moderate mitotic activity includes nonkeratinizing/basaloid squamous cell carcinomas, neuroendocrine neoplasms, and melanoma.
Preponderance of Blast-Like Cells
Presence of Rare Large Pleomorphic Cells
This group has a negative FCM study, cannot be diagnosed in cell blocks, and requires representative CNB or excisional biopsy specimens for diagnosis ❚Image 1E❚. The differential diagnosis includes viral infections, lymphoproliferative disorders in immunocompromised settings, CHL, NLPHL, T-cell/histiocyte-rich large B-cell lymphoma (TCRBCL), ALCL, and partial involvement by a nonhematopoietic neoplasm. For hematopoietic tumors, a typical panel includes CD3, CD15, CD20, CD30, CD43, CD45, PAX5, ALK, and EBV-ISH/CISH. The goal in these cases is to determine the immunophenotype of the large pleomorphic cells. Benign cells in the background are expected to be positive for some of the markers in the panel (CD3/CD43, T cells; CD15, granulocytes and monocytes; CD20/PAX5, B cells; CD30, activated leukocytes; CD45, all leukocytes), and this needs to be considered during evaluation. The diagnosis of CHL relies on the demonstration of Reed-Sternberg/Hodgkin cells (RS/HCs). The most consistent phenotype of RS/ HCs is CD20-/PAX5+/CD30+. Expression of CD15 is inconsistent but very helpful when present. Reported rates of CD15 expression vary from 37% to 85% depending on the clone used. The best results are achieved using the MMA/LeuM1 clone (Cell Marque, Hot Springs, AR) with a reported sensitivity of approximately 85% and specificity of around 93%. 39 CD45 is negative, but it can be difficult to interpret due to neighboring reactive cells that create a false membranous positivity, yet most hematopoietic neoplasms, including lymphomas, show diffuse cytoplasmic, not membranous, positivity. 40 Focal, usually weak, expression of CD20 is not uncommon (~35%), but consistent strong expression of CD20 in all RS/HCs is very unusual and warrants reconsidering the diagnosis. 14, 40 Reported rates of strong expression of CD20 in a substantial proportion of RS/HCs (20%-70%) vary from 5% to 13% and appear to be more common in older patients. The clinical presentation, stage, clinical course, and response to therapy do not differ from conventional CD20-negative cases. 41, 42 In equivocal cases, additional pan-B-cell markers (CD19, CD79a, BOB.1, and OCT-2), which are negative in CHL and positive in non-Hodgkin lymphomas, are necessary. Another source of potential confusion includes primary mediastinal B-cell lymphoma and nonmediastinal "gray-zone lymphoma," which in biopsy specimens demonstrate overlap between CHL and DLBCL, with foci resembling one or the other entity or with areas that show overlapping histologic features of both. These findings are coupled with immunophenotypic aberrancies, where cases with histologic features of CHL and CD30 expression also express CD45 and show strong and diffuse reactivity for CD20 and CD79a. Similarly, some cases of mediastinal lymphoma may show characteristic primary mediastinal B-cell lymphoma histology but loss of common B-cell antigens and expression of CD30 and CD15, along with B-cell associated transcription factors such as PAX5, BOB1, and OCT2. A diagnosis of B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and CHL, should be considered for these cases. 43, 44 A small subset of CHL may express T-cell antigens other than CD3, including CD43, making it difficult to separate CHL from ALCL 45, 46 ; the consistent expression of PAX5 in CHL but not ALCL is particularly useful in this scenario. In EBV-positive cases, only the RS cells are positive. In contrast, in EBV infection/reactivation or other EBV-associated lymphomas, most B cells, small and/or large, are positive, and the RS/HC-like cells express CD20 and CD45. ALCL can have many morphologic patterns; while most cases show confluent sheets of large cells, some closely mimic CHL and are classified as ALCL-Hodgkin-like pattern/ variant. 14, 40, 45 The most consistent phenotype of ALCL is CD15-/CD20-/PAX5-/CD30+; CD3 is very inconsistent but definitive when present; CD45 is frequently negative, but other T-cell associated and cytotoxic markers (CD4, CD5, CD7, CD43, TIA1, granzyme B, and epithelial membrane antigen [EMA] ) are frequently positive. 40, 45 ALK-positive ALCL is much more common in children and adults younger than 30 years.
14 While the prognosis of ALK-positive and ALK-negative ALCL cases is similar in patients younger than 40 years, the ALK status and clinical stage are considered the most relevant prognostic factors for patients 40 years or older. 14, 46 In cases in which the immunohistochemical workup cannot resolve the differential CHL vs ALCL, a positive T-cell receptor gene rearrangement study would be diagnostic of ALCL, but a negative result would make a repeat biopsy, preferably an excisional biopsy, necessary for definitive diagnosis (Table 2) . ALK-positive cases that are negative for pan-T, pan-B, and cytotoxic markers need to be tested for plasma cell markers (CD38, CD138, MUM1, cytoplasmic immunoglobulins/light chains) and/or BOB.1 and OCT-2. Cases positive for these markers are classified as ALK-positive large B-cell lymphoma (ALK+ LBCL). In contrast to plasmablastic lymphomas, these cases usually affect young immunocompetent individuals, are either weak or negative for CD30, and are not associated with immunosuppression, human immunodeficiency virus, EBV, or human herpesvirus 8 infection. The clinical course of reported cases has been very aggressive, with very short survivals except for those with early stage disease. 47 Targeted therapy with the ALK inhibitor crizotinib has proven beneficial for ALK-positive ALCL but has achieved only partial transient responses in ALKpositive LBCL. TCRBCL and NLPHL are CD20+/ PAX5+/CD30-/CD45+/EBV-. In the former, reactive T cells predominate, clinical progression is rapid, and clinical stage is usually high; in NLPHL, reactive B cells usually predominate, clinical progression is slow, and clinical stage is usually low. 48 In needle core or excisional biopsy specimens, the presence of nodular arrangements of reactive B cells is diagnostic of NLPHD regardless of the number of reactive T cells, and the absence of B-cell nodules, especially in the context of aggressive disease, is consistent with TCRBCL. A subset of NLPHD may show marked preponderance of T cells, making its distinction from TCRBCL difficult in limited samples. These cases may show a nodular or diffuse architecture described as "pattern D/T-cell-rich nodular" and "pattern E/diffuse T-cell rich" by Fan et al. 49 In these cases, a diagnosis of NLPHL relies on the identification of B-cell nodules at low power on the CD20 immunostain. T-cell-rich variants of NLPHL are more common in older lesions and correlate with indolent biology 48 ; a history of longstanding asymptomatic lymphadenopathy would be typical for NLPHL but highly unusual for TCRBCL. In cases where this differential cannot be resolved, an excisional biopsy should be requested. Nonhematopoietic differential diagnosis for rare large pleomorphic cells includes melanomas and pleomorphic carcinomas.
When to Refer for Consultation
The answer to this question varies for every pathologist. We refer cases in which consensus among colleagues cannot be reached, cases considered "unusual, atypical or reportable" and cases in which there is no diagnostic certainty despite adequate sampling. Discussion with the oncologist if the entertained differential will result in different management helps guide the decision to refer.
Special Considerations in Previously Treated Patients
Special aspects of the diagnostic interpretation of samples from previously treated patients include the following:
• Loss of target antigens from the cell surface (eg, loss of CD20 in patients treated with rituximab, CD30 following treatment with brentuximab, or multiple target antigens following treatment with chimeric antigen receptor T cells) [50] [51] [52] • Insufficient/limited diagnostic material in samples obtained from lymph nodes or other sites that are necrotic or fibrotic following chemotherapy or radiation therapy 53 • The need to determine if residual lymphoma or minimal residual disease is present following treatment 52, 53 Interpretation of biopsy specimens after therapy can be difficult and requires considering potential confounders like tumor viability, radiation atypia, sample adequacy, and the possibility of histologic transformation. 54 Correlation with serial CT and PET/CTs, clinical symptoms, and laboratory parameters of disease activity (LDH, β2-microglobulin) for evaluation of response to therapy, disease progression, potential transformation, and the prospect of participating in specific clinical trials will determine the need to undergo repeat or additional sampling. The specific goals, potential biopsy targets, diagnostic yield, limitations, and risks associated with repeat limited vs excisional sampling are best determined at multidisciplinary conferences with the participation of radiologists, hematologists, surgeons, and pathologists.
Special Considerations for Limited Samples
• Widespread availability and decreased costs have resulted in frequent application of immunophenotyping and molecular studies that can detect small clonal lymphoid populations by monotypic sIg expression, demonstration of clonal B-or T-cell gene rearrangements, or the presence of signature translocations (eg, IGH/BCL2). The revised fourth edition of the WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues cautions against overdiagnosis of these small clonal populations as lymphomas in the absence of clinical disease. 14 Entities such as "in situ" follicular or mantle cell neoplasia are now included as formal subcategories of FL and MCL, respectively, and expectant follow-up is recommended for these cases. Special caution is also necessary in younger patients (aged <18 years), in whom transient monoclonal B-cell populations can be found in reactive follicular hyperplasias or who may have the pediatric variant of FL or nodal MZL, characterized by a localized/ low-stage, extremely indolent course and treated with local therapies and expectant follow-up. 55, 56 • Incidental, indolent low-grade lymphoid neoplasms are common in the elderly; if this diagnosis does not explain the clinical scenario, it is prudent to keep looking for alternative explanations.
• Some lymphomas (less frequently nonhematopoietic tumors) may elicit formation of sarcoid-type granulomas or prominent diffuse granulomatous reactions (CHL, MZL, LPL, certain peripheral T cell) that may obscure their diagnosis. If the cause of the granulomas is not evident, ancillary studies become critical for detecting hidden tumor populations; T and B gene rearrangement studies can be useful in this context. If a neoplasm is not apparent, recommend follow-up and repeat biopsy.
• Lymphomas frequently induce sclerosis, especially in the retroperitoneum; before making a diagnosis of a fibroinflammatory or IgG4-related disorder (eg, retroperitoneal fibrosis, sclerosing mesenteritis), it is imperative to perform a thorough diagnostic workup to exclude lymphomas and recommend clinical follow-up.
• Plasma cell neoplasms and high-grade neoplasms with plasmacytic differentiation overlap immunophenotypically with carcinomas; both are CD3-/CD20-/PAX5-/ CD45-/CD138+/EMA+. These neoplasms are usually CD43+, and this is one of the arguments in favor of using CD43 and CD45 as a cocktail in the evaluation of neoplasms of uncertain lineage. CD138, the most commonly used marker for identifying plasma cells, is also expressed by most benign and malignant epithelia and a few mesenchymal tumors with epithelial differentiation (eg, synovial sarcoma). Additional plasma cell markers-CD38, CD79a, cytoplasmic heavy or light chains, MUM1, and cytokeratin cocktail-are needed to resolve this differential. Although differentiated plasma cells have an easily recognizable morphology, their morphologic spectrum is very broad, ranging from small mature lymphocyte-like cells to cases with BL-like or anaplastic morphology. 57 At the same time, plasmacytoid morphology is common in neuroendocrine, myoepithelial, and plasmacytoid variants of carcinomas (eg, urothelial, lobular). Awareness of the immunomorphologic overlap between these groups of tumors is important to avoid serious misdiagnosis.
• Plasma cell neoplasms and high-grade neoplasms with plasmacytic differentiation overlap immunophenotypically and morphologically with melanoma. Both neoplasms frequently appear as discohesive plasmacytoid cells with variably prominent nucleoli in cytologic preparations. Cell size and degree of cytologic atypia can vary considerably in both groups. Immunophenotypically, both are consistently negative for pankeratin, CD3, CD19, CD20, CD45, PAX5, synaptophysin, and chromogranin; positive for vimentin; and frequently positive for CD10, CD31, CD44, CD56, CD117, CD138, and MUM1. 24, 58 A panel including immunoglobulin light chains and melanocytic markers (S100 and/or Sox10) can resolve this differential diagnosis. 59 
Conclusions
Careful selection of the biopsy target and intraprocedural assessment and triaging of the specimen maximize the likelihood that diagnostic, prognostic, and therapeutically relevant information will be obtained from limited samples. In limited samples, morphologic evaluation is limited and requires the support of ancillary studies and careful correlation with the clinical scenario. FCM is pivotal for lesions with a preponderance of small lymphocytes but less relevant in high-grade lesions or lesions with rare abnormal cells where the differential diagnosis is much broader. MYC FISH should be performed in all high-grade lymphoid lesions, and positive cases always require additional FISH studies for BCL2 and BCL6 rearrangements to evaluate for DHL/ THL. Amplification of MYC and BCL2 and/or BCL6, as well as MYC REA superimposed on preexisting lymphomas, correlates with an aggressive disease course like DHL/THL. Overexpression of MYC and BCL2 (double expressor DLBCL/HGBCL) is common in non-GCB DLBCL/HGBCL with high proliferative rates, and it correlates with more aggressive behavior than standard DLBCL but less than DHL/THL. Evaluation for possible Hodgkin lymphoma and entities in its differential diagnosis cannot be done in FNA and requires a biopsy. Evaluation of limited samples after therapy requires familiarity with potential effects of therapy in the morphology and immunophenotype of neoplastic cells; correlation with laboratory and imaging findings to determine response to therapy, progression, or possible transformation; and, in cases needing repeat sampling, discussion of site and type of procedure to be performed at multidisciplinary conferences. High-grade plasma cell neoplasms and high-grade lymphomas with plasmacytic differentiation overlap morphologically and phenotypically with high-grade carcinomas and melanomas, needing broad diagnostic panels that include numerous mutually exclusive lineage-specific markers. While the number of diagnostic categories continues to grow with each iteration of the WHO classification of lymphoid tumors, most of the lesions routinely encountered in clinical practice have been covered in this article. We hope it provides useful guidance for the workup, diagnosis, and differential diagnosis of these lesions in limited samples.
